PLATFORM WITH A SUCCESSFUL TRACK RECORD

OUR PIPELINE

Paradox Programs

Target

Discovery

Stage

Pre-clinical

Phase I

Phase II

Phase III

LX-96

AL Heart Failure

IgG Light Chains

Pre-clinical
MORE INFO
Paradox has developed LX-96, a specialized monoclonal antibody designed for the potential treatment of late-stage immunoglobulin light chain (AL)  amyloidosis.

LX-96 aims to specifically target and clear the diseased form of immunoglobulin light chains that aggregate and deposit in organs, while leaving healthy light chain proteins in the body untouched.  
Quick Facts: AL amyloidosis
  • Most common type of amyloidosis in the USA
  • Prevalence: 30,000-45,000 patients in the USA and EU
  • Incidence: 4,000-4,500 patients
  • Disease mechanism: Light chain proteins are overproduced, misfold, and accumulate as toxic deposits in organs such as the heart, kidney, and liver.
  • Results in fatal multi-organ failure: heart, kidney, liver
Immune cells actively clearing diseased light chains (turning orange) when LX-96 is administered

KX-99

ALECT2 Amyloidosis

LECT2 Proteins

Discovery
MORE INFO
Paradox has developed KX-99, a specialized monoclonal antibody for ALECT2 amyloidosis, an orphan disease for which no frontline treatment currently exists. 

KX-99 aims to specifically target the diseased form of LECT2 proteins that aggregate and deposit as toxic amyloid in organs, causing chronic kidney disease and renal failure.
Quick Facts: ALECT2 Amyloidosis
  • 3rd most common type of amyloidosis in the USA
  • US Prevalence: ~3,200 patients, although severely underdiagnosed
  • Strong ethnic bias: Hispanic, Native American, American Indian, Punjabi, Egyptian, Sudanese, Chinese populations
  • Disease mechanism: LECT2 proteins are overproduced by the liver, misfold and accumulate as toxic deposits in organs such as the kidney, liver, spleen, gallbladder

NX-86

Neurodegenerative Disease

Undisclosed

Discovery
MORE INFO
Top Secret for now - stay tuned!